Global Information
회사소개 | 문의 | 비교리스트

방광암 시장과 예측 분석

Bladder Cancer Market and Forecast Analysis

리서치사 Datamonitor Healthcare
발행일 2018년 07월 상품 코드 858275
페이지 정보 영문 199 Pages
가격
US $ 22,000 ₩ 25,999,000 PDF by E-mail (Single User License)
US $ 107,800 ₩ 127,398,000 PDF by E-mail (Global License)


방광암 시장과 예측 분석 Bladder Cancer Market and Forecast Analysis
발행일 : 2018년 07월 페이지 정보 : 영문 199 Pages

세계의 방광암(Bladder Cancer) 시장은 면역치료의 성장에 의해 촉진되어 2025년까지 48억 달러에 달할 것으로 예측됩니다. 2017-2037년간 미국, 일본 및 EU 주요 5개국 시장의 방광암 발증 사례는 40% 이상 증가할 것으로 예측됩니다.

세계의 방광암 치료제 시장에 대해 조사했으며, 주요 시장의 시장 규모와 예측 및 치료제별 판매 실적과 예측, 치료 동향, 역학 및 임상 파이프라인 개요 등을 정리하여 전해드립니다.

예측 : 방광암

  • 개관
  • 개요
  • 시장 개요·동향
  • 시장 정의·조사 방법
  • BAVENCIO(AVELUMAB)
  • CYRAMZA(RAMUCIRUMAB)
  • ERDAFITINIB
  • IMFINZI(DURVALUMAB)
  • KEYTRUDA(PEMBROLIZUMAB)
  • OPDIVO(NIVOLUMAB)
  • TECENTRIQ(ATEZOLIZUMAB)
  • 1차 조사 방법

치료 : 방광암

  • 개관
  • 개요
  • 1차 조사 방법
  • 질병의 정의·진단
  • 환자 세분화
  • 현재 치료 옵션
  • 처방 동향

역학 : 방광암

  • 개요
  • 질병의 배경
  • 조사 방법
  • 예측
  • 참고 자료

출시약 : 방광암

  • 개관
  • 개요
  • 제품 개요
  • 제품 개요 : BAVENCIO
  • 제품 개요 : IMFINZI
  • 제품 개요 : KEYTRUDA
  • 제품 개요 : OPDIVO
  • 제품 개요 : TECENTRIQ

파이프라인 : 방광암

  • 개관
  • 개요
  • 임상 파이프라인 개요
  • 임상시험 설계
  • 주요 파이프라인의 방광내 치료제
  • PHARMA INTELLIGENCE의 파이프라인 리소스
  • 제품 개요(후기 단계) : ERDAFITINIB
KSA 19.06.18

Overview

Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections. Urothelial carcinoma, also known as transitional cell carcinoma, accounts for over 90% of bladder cancers. Approximately three-quarters of urothelial carcinoma patients initially present with non-muscle invasive bladder cancer (NMIBC), which is associated with a relatively good prognosis. However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.

Market Snapshot

  • The value of the bladder cancer market is projected to reach $4.8bn by 2025, with growth driven by immunotherapies.
  • Pharmacological treatment of urothelial bladder cancer is dominated by platinum-based chemotherapy regimens.
  • Between 2017 and 2037, incident cases of bladder cancer will increase by over 40% in the US, Japan, and five major EU markets.
  • Immunotherapy developers will seek label expansions in a variety of treatment settings to differentiate their products.
  • Late-phase targeted therapies will look to address needs not met by immunotherapies.

TABLE OF CONTENTS

FORECAST: BLADDER CANCER (Published on 04 July 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • BAVENCIO (AVELUMAB)
  • CYRAMZA (RAMUCIRUMAB)
  • ERDAFITINIB
  • IMFINZI (DURVALUMAB)
  • KEYTRUDA (PEMBROLIZUMAB)
  • OPDIVO (NIVOLUMAB)
  • TECENTRIQ (ATEZOLIZUMAB)
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: BLADDER CANCER (Published on 05 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: BLADDER CANCER (Published on 19 July 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY

MARKETED DRUGS: BLADDER CANCER (Published on 04 July 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: BAVENCIO
  • PRODUCT PROFILE: IMFINZI
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE: OPDIVO
  • PRODUCT PROFILE: TECENTRIQ

PIPELINE: BLADDER CANCER (Published on 04 July 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • CLINICAL TRIAL DESIGN
  • KEY PIPELINE INTRAVESICAL THERAPIES
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): ERDAFITINIB

LIST OF FIGURES

  • Figure 1: Bladder cancer market value in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Bladder cancer market value in the US, Japan, and five major EU markets, by drug class, 2016-25
  • Figure 3: Sales of PD-1/PD-L1 inhibitors for bladder cancer in the US, Japan, and five major EU markets, by brand, 2016-25
  • Figure 4: Sales of Cyramza and erdafitinib for bladder cancer in the US, Japan, and five major EU markets, by brand, 2016-25
  • Figure 5: Patient-based forecast methodology for bladder cancer
  • Figure 6: Price sources and calculations, by country
  • Figure 7: Bavencio sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 8: Cyramza sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 9: Erdafitinib sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 10: Imfinzi sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Keytruda sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 12: Opdivo sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 13: Tecentriq sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 14: Distribution of bladder cancer patients across the US, Japan, and five major EU markets, by stage and country
  • Figure 15: Percentage of NMIBC patients who receive each type of treatment, by country
  • Figure 16: Top three intravesical therapies for NMIBC, by country
  • Figure 17: Percentage of MIBC patients who receive each type of treatment, by country
  • Figure 18: MIBC patients treated with cystectomy and systemic therapy who receive adjuvant chemotherapy, neoadjuvant chemotherapy, or both, by country
  • Figure 19: Top three regimens used in the neoadjuvant treatment of MIBC patients, by country
  • Figure 20: Top three regimens used in the adjuvant treatment of MIBC patients, by country
  • Figure 21: Percentage of Stage IV bladder cancer patients who receive each treatment type, by country
  • Figure 22: Top three regimens used in the first-line treatment of Stage IV bladder cancer patients, by country
  • Figure 23: Top three regimens used for second-line treatment of Stage IV bladder cancer patients, by country
  • Figure 24: Percentage of local relapse bladder cancer patients who receive each treatment type, by country
  • Figure 25: Top three regimens used for first-line treatment of local relapse bladder cancer, by country
  • Figure 26: Percentage of distant relapse bladder cancer patients who receive each treatment type, by country
  • Figure 27: Top three regimens used for first-line treatment of distant relapse bladder cancer, by country
  • Figure 28: Trends in incident cases of bladder cancer in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 29: Bavencio for urothelial bladder cancer - SWOT analysis
  • Figure 30: Datamonitor Healthcare's drug assessment summary for Bavencio in urothelial bladder cancer
  • Figure 31: Datamonitor Healthcare's drug assessment summary for Bavencio in urothelial bladder cancer
  • Figure 32: Imfinzi for urothelial bladder cancer - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary for Imfinzi in urothelial bladder cancer
  • Figure 34: Datamonitor Healthcare's drug assessment summary for Imfinzi in urothelial bladder cancer
  • Figure 35: Keytruda for urothelial bladder cancer - SWOT analysis
  • Figure 36: Datamonitor Healthcare's drug assessment summary for Keytruda in urothelial bladder cancer
  • Figure 37: Datamonitor Healthcare's drug assessment summary for Keytruda in urothelial bladder cancer
  • Figure 38: Opdivo for urothelial bladder cancer - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary for Opdivo in urothelial bladder cancer
  • Figure 40: Datamonitor Healthcare's drug assessment summary for Opdivo in urothelial bladder cancer
  • Figure 41: Tecentriq for urothelial bladder cancer - SWOT analysis
  • Figure 42: Datamonitor Healthcare's drug assessment summary for Tecentriq in urothelial bladder cancer
  • Figure 43: Datamonitor Healthcare's drug assessment summary for Tecentriq in urothelial bladder cancer
  • Figure 44: Erdafitinib for urothelial bladder cancer - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary for erdafitinib in urothelial bladder cancer
  • Figure 46: Datamonitor Healthcare's drug assessment summary for erdafitinib in urothelial bladder cancer

LIST OF TABLES

  • Table 1: Bladder cancer market value in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Bladder cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2016-25
  • Table 3: Sales of PD-1/PD-L1 inhibitors for bladder cancer in the US, Japan, and five major EU markets, by brand ($m), 2016-25
  • Table 4: Sales of Cyramza and erdafitinib for bladder cancer in the US, Japan, and five major EU markets, by brand ($m), 2016-25
  • Table 5: Summary of drug classes and molecules in Datamonitor Healthcare's bladder cancer forecast, 2016-25
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Patent expiry dates for key marketed brands in bladder cancer in the US, Japan, and five major EU markets, 2016-25
  • Table 8: Estimated launch dates of key pipeline products and marketed brands in bladder cancer in the US, Japan, and five major EU markets, 2016-25
  • Table 9: Bavencio sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 10: Bavencio patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 11: Cyramza sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 12: Cyramza patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 13: Erdafitinib sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 14: Erdafitinib patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 15: Imfinzi sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 16: Imfinzi patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 17: Keytruda sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Keytruda patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 19: Opdivo sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 20: Opdivo patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 21: Tecentriq sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 22: Tecentriq patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 23: Medical oncologists and urologists surveyed for the urothelial bladder cancer primary research study, 2016
  • Table 24: Medical oncologists and urologists surveyed for the urothelial bladder cancer primary research study, 2016
  • Table 25: Bladder cancer five-year survival rates in the US, by stage at diagnosis
  • Table 26: TNM classification of bladder cancer, by stage at diagnosis
  • Table 27: Leading treatments for bladder cancer
  • Table 28: T staging within the TNM classification of bladder cancer
  • Table 29: International Classification of Diseases topography codes for bladder cancer
  • Table 30: Cancer registry databases used as a source of bladder cancer incidence data, by country
  • Table 31: Sources of survival data used to estimate bladder cancer prevalence, by country
  • Table 32: Validation of forecast estimates against benchmark estimates, by country
  • Table 33: Incident cases of bladder cancer in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 34: Key marketed products for bladder cancer
  • Table 35: Bavencio drug profile
  • Table 36: Bavencio pivotal trial data in urothelial bladder cancer
  • Table 37: Bavencio ongoing late-phase trials in urothelial bladder cancer
  • Table 38: Imfinzi drug profile
  • Table 39: Imfinzi pivotal trial data in urothelial bladder cancer
  • Table 40: Imfinzi ongoing late-phase trials in urothelial bladder cancer
  • Table 41: Keytruda drug profile
  • Table 42: Keytruda pivotal trial data in urothelial bladder cancer
  • Table 43: Keytruda ongoing late-phase trials in urothelial bladder cancer
  • Table 44: Keytruda early-phase data in urothelial bladder cancer
  • Table 45: Opdivo drug profile
  • Table 46: Opdivo pivotal trial data in urothelial bladder cancer
  • Table 47: Opdivo ongoing late-phase trials in urothelial bladder cancer
  • Table 48: Tecentriq drug profile
  • Table 49: Tecentriq pivotal trial data in urothelial bladder cancer
  • Table 50: Tecentriq ongoing late-phase trials in urothelial bladder cancer
  • Table 51: Late-phase pipeline products in development for urothelial bladder cancer
  • Table 52: BC-819 drug profile
  • Table 53: Instiladrin drug profile
  • Table 54: Vicinium drug profile
  • Table 55: Erdafitinib drug profile
  • Table 56: Key erdafitinib Phase II trial in urothelial bladder cancer
  • Table 57: Erdafitinib early-phase data in urothelial bladder cancer
Back to Top
전화 문의
F A Q